MedTrace Logo

The Norwegian Antirheumatic Drug Register

NCT01581294 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2022-08-23

No results posted yet for this study

Summary

NOR-DMARD is a register-based longitudinal observational study of which the main objectives are to study the effectiveness of treatment of inflammatory joint diseases with biological disease modifying anti-rheumatic drugs (DMARDs) in clinical practice, by measuring disease activity, health related quality of life, function and joint damage, and to study the long-term safety of such treatment. Other objectives include the assessment of cost-effectiveness of treatment, to identify and and validate clinical, genetic and immunological predictors of efficacy and adverse events, to assess the impact of treatment with biological DMARDs on work participation and work productivity, to investigate different strategies for use of biological DMARDs, to assess the performance of different outcome measures, and to ensure a systematic and timely follow-up of patients treated with biological DMARDs.

Conditions

  • Inflammatory Joint Diseases

Sponsors & Collaborators

  • University Hospital of North Norway

    collaborator OTHER

  • St. Olavs Hospital

    collaborator OTHER

  • Lillehammer Hospital for Rheumatic Diseases

    collaborator OTHER

  • Vestre Viken Hospital Trust

    collaborator OTHER

  • Helse Forde

    collaborator OTHER

  • Diakonhjemmet Hospital

    lead OTHER

Principal Investigators

  • Tore K Kvien, MD, PhD · Diakonhjemmet Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2050-12-31
Completion
2050-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01581294 on ClinicalTrials.gov